AIDS

1. HAGINS D, Berhe M, Crofoot GE, Ramgopal MN, et al
   Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV: randomized study.
   AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004372.
   

   >> Share

   
   
2. JAO J, Gochanour C, Williams PL, Schenkel S, et al
   Pubertal onset in children with in utero HIV/antiretroviral exposure in Botswana.
   AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004374.
   

   >> Share

   
   

   
   Clin Infect Dis

3. SERRANO-VILLAR S, Martin-Pedraza L, Tiraboschi J, Novella M, et al
   Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study).
   Clin Infect Dis. 2025 Oct 10:ciaf565. doi: 10.1093.
   

   >> Share

   
   
4. KOETHE JR
   Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
   Clin Infect Dis. 2025 Oct 10:ciaf566. doi: 10.1093.
   

   >> Share

   
   

   
   HIV Med

5. SCHUETTFORT G, Borch J, Cabello A, Crusells M, et al
   Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.
   HIV Med. 2025 Oct 7. doi: 10.1111/hiv.70119.
   

   >> Share

   
   
6. CHAN P, Moreland S, Sacdalan C, Colby DJ, et al
   Blood pressure and metabolic outcomes after efavirenz- or dolutegravir-based therapy started in acute HIV infection.
   HIV Med. 2025;26:1619-1625.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share